MAP, JOIN AND DRIVE EUROPEAN ACTIVITIES FOR ADVANCED THERAPY MEDICINAL PRODUCT D...
MAP, JOIN AND DRIVE EUROPEAN ACTIVITIES FOR ADVANCED THERAPY MEDICINAL PRODUCT DEVELOPMENT AND IMPLEMENTATION FOR PATIENT AND SOCIETY BENEFIT
Advanced Therapy Medicinal Products (ATMPs) are medicines based on genes, cells and tissues for human use. They can provide patients novel treatment alternatives to significantly improve or even cure diseases that currently have n...
Advanced Therapy Medicinal Products (ATMPs) are medicines based on genes, cells and tissues for human use. They can provide patients novel treatment alternatives to significantly improve or even cure diseases that currently have no or inadequate standard-of-care options. However, significant challenges remain for the scientific, clinical and patient communities as well as commercial entities and regulatory, policy-making and technology-assessing bodies. The JOIN4ATMP consortium unites international experts and stakeholders with the mission to accelerate and de-risk European ATMP development and ensure wide-spread equitable ATMP access for patients with common diseases, rare non-cancer diseases and rare cancers in Europe. It brings together all members of the European University Hospital Alliance with the existing EU-funded T2EVOLVE and RESTORE networks, and with active support from industry partners and patient representatives as our 14 core partners. The core partners are joined by supporting partners active in ATMP development, production, application and regulation. Our team will use real-world data and experiences to achieve the most rapid and holistic map of current hurdles and the best way to improve support and regulation of ATMP development and use in the EU and associated countries. The JOIN4ATMP end-product will be a state-of-the-art information package circumscribing (i) currently existing and potential future hurdles preventing rapid and streamlined ATMP development and clinical translation and (ii) a defined set of recommendations to overcome these hurdles in a manner guaranteeing equitable access for patients throughout Europe. We are committed to the long-term operation of our network and take steps to assure its sustainability in order to inform and coordinate activities in Europe for the ATMP field, which will only gain in importance with the advance of personalized medicine in the future.ver más
05-11-2024:
Cataluña Gestión For...
Se abre la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:
04-11-2024:
Doctorados industria...
Se ha cerrado la línea de ayuda pública: Formación de doctores y doctoras de las universidades del Sistema universitario de Galicia (SUG) en empresas y centros de innovación y tecnología para el organismo:
04-11-2024:
PERTE-AGRO2
Se ha cerrado la línea de ayuda pública: PERTE del sector agroalimentario
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.